Somatic Gene Changes Associated with Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

被引：0
作者：
Pachimatla, A. G. [1 ]
Kalvapudi, S. [1 ]
Bawek, S. [2 ]
Vedire, Y. [1 ]
Jain, P. [1 ]
Yendamuri, S. [1 ]
Patnaik, S. [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Buffalo, Buffalo, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
immunotherapy response; gene mutations; KRAS and TP53;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.11A.06
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [31] EGFR mutation status in a series of Turkish non-small cell lung cancer patients
    Calibasi-Kocal, Gizem
    Amirfallah, Arsalan
    Sever, Tolga
    Unal, Olcun Umit
    Gurel, Duygu
    Oztop, Ilhan
    Ellidokuz, Hulya
    Basbinar, Yasemin
    BIOMEDICAL REPORTS, 2020, 13 (02) : 1 - 9
  • [32] Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
    Price, Katharine A.
    Azzoli, Christopher G.
    Krug, Lee M.
    Pietanza, Maria C.
    Rizvi, Naiyer A.
    Pao, William
    Kris, Mark G.
    Riely, Gregory J.
    Heelan, Robert T.
    Arcila, Maria E.
    Miller, Vincent A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1623 - 1629
  • [33] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [34] Association of Mutation Profiles with Postoperative Survival in Patients with Non-Small Cell Lung Cancer
    Goto, Taichiro
    Kunimasa, Kei
    Hirotsu, Yosuke
    Nakagomi, Takahiro
    Yokoyama, Yujiro
    Higuchi, Rumi
    Otake, Sotaro
    Oyama, Toshio
    Amemiya, Kenji
    Mochizuki, Hitoshi
    Omata, Masao
    CANCERS, 2020, 12 (11) : 1 - 16
  • [35] Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
    Shen, Fangfang
    Guo, Wei
    Song, Xia
    Wang, Bei
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
  • [36] Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer
    Sharma, Namita
    Graziano, Stephen
    CANCER TREATMENT REVIEWS, 2018, 69 : 143 - 151
  • [37] BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
    Leonetti, Alessandro
    Facchinetti, Francesco
    Rossi, Giulio
    Minari, Roberta
    Conti, Antonia
    Friboulet, Luc
    Tiseo, Marcello
    Planchard, David
    CANCER TREATMENT REVIEWS, 2018, 66 : 82 - 94
  • [38] The relevance of the reference range for EGFR testing in non-small cell lung cancer patients
    Pisapia, Pasquale
    Russo, Alessandro
    De Luca, Caterina
    Pepe, Francesco
    Drago, Francesco
    Rolfo, Christian
    Troncone, Giancarlo
    Malapelle, Umberto
    LUNG CANCER, 2024, 198
  • [39] Third-Generation Tyrosine Kinase inhibitors Targeting epidermal Growth Factor Receptor Mutations in non-Small Cell Lung Cancer
    Barnes, Tristan A.
    O'Kane, Grainne M.
    Vincent, Mark David
    Leighl, Natasha B.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [40] Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
    Wang, Shouzheng
    Li, Junling
    ONCOTARGETS AND THERAPY, 2019, 12 : 6535 - 6548
12345